氟尿嘧啶pH依赖-时滞型结肠定位微丸的制备及释药特性研究

 目的制备pH依赖-时滞型氟尿嘧啶(5-FU)结肠定位微丸并对其体外释药情况及影响因素进行研究。方法采用挤出-滚圆法制备空白丸芯,将药物与溶胀材料和黏合剂混合,采用空白丸芯上药法制备载药丸芯,以乙基纤维素为控释层包衣材料,Eudragit FS 30D为肠溶层材料,流化包衣法制备pH依赖-时滞型5-FU结肠定位释药微丸,以释放度为评价指标,考察影响5-FU微丸体外释药的因素。结果溶胀层材料的种类及厚度、控释层及肠溶层包衣厚度等对释药速率均有影响。将5-FU和羟甲基淀粉酶(CMS-Na)混合作为溶胀层,乙基纤维素有机溶液作为控释层,Eudragit FS 30D为肠溶层制备的结肠定位包衣微丸,当溶胀层增重30%,控释层增重12%和肠溶层增重20%时,在模拟人体胃肠道pH变化条件下,微丸释药特性基本符合设计要求,达到了结肠定位的效果。结论通过调整溶胀层,控释层,肠溶层包衣厚度可以制备5-FUpH依赖-时滞型结肠定位微丸。     

白头翁总皂苷-羟丙基-β-环糊精包合物结肠靶向微丸的制备

目的：制备白头翁总皂苷结肠靶向微丸。方法：采用水溶液-搅拌法制备白头翁总皂苷-羟丙基-β-环糊精包合物,再以制粒-滚圆法制备微丸,利用Glatt流化床进行包衣。结果：白头翁总皂苷微丸2 h溶出度为16.0%,而包合物微丸0.5 h溶出度达91.9%。以Eudragit S100为包衣材料、TEC为增塑剂、滑石粉为抗黏剂、包衣增重为12%时,包衣效率高,几乎无黏结现象,包衣微丸在人工胃液中2 h几乎无药物释放,人工小肠液4 h药物累积释放度小于15%,人工结肠液4 h药物累积释放度大于90%。结论：白头翁总皂苷-羟丙基-β-环糊精包合物包衣微丸具有良好的体外结肠靶向释药特征,可进一步研制成口服结肠靶向制剂。     

苦参碱时控型结肠定位给药微丸的制备和体外释药研究

 目的 用流化床包衣技术制备苦参碱时控型结肠定位给药微丸。 方法 使用流化床包衣设备,首先在空白丸芯上采用溶液上药法制备苦参碱载药微丸,然后以羟丙甲纤维素（ HPMC ）和乙基纤维素水分散体（ Surelease ）的混合物包衣作为溶胀控释层,以 Surelease 包衣作为时控包衣层,制备时控型结肠定位给药微丸。分别用扫描电镜、溶出度测定和光学显微镜考察微丸的包衣质量、体外释药率和释放过程中微丸的变化。 结果 药物通过时控层破裂开始大量释放 , 调节该层增重和溶胀控释层的增重及此层中 HPMC 与 Surelease 比例,均可以调节释药时滞 , 控制药物的释放速度。优化后的包衣微丸在模拟胃肠道 pH 情况下延迟 5 h 释药,之后药物近恒速释放, 16 h 内药物释放完全。 结论 可通过调节时控层的增重 , 溶胀控释层的增重及此层中 HPMC 与 Surelease 比例来制备不同时滞的苦参碱时控型结肠定位给药微丸,为小分子水溶性药物制成时控型延迟释药微丸提供参考。     

新型载姜黄素结肠定位胶囊的制备及其体外释药行为研究

目的 制备载姜黄素结肠定位胶囊并对其体外释药行为进行研究。方法 采用灌注法制备非渗透性胶囊体,滴制法制备载姜黄素自微乳微丸,粉末直接压片法压制柱塞片,将其组装成柱塞型胶囊,考察影响释药时滞的各种因素,评价其体外释药行为。结果 该柱塞型胶囊的释药时滞随柱塞片中高酯果胶/乳糖比例的增加而延长,随柱塞片片质量的增加而延长。具有相同处方柱塞片的胶囊在0.5%果胶酶柠檬酸盐缓冲液和5%大鼠盲肠内容物溶液中的释药时滞明显缩短,说明其具有酶促发性。结论 通过调节柱塞片处方组成及片质量可获得具有适当释药时滞的结肠定位胶囊。     

5-氨基水杨酸结肠定位渗透泵微丸在大鼠体内释药特性考察

目的:考察基于渗透泵酶触发原理的5-氨基水杨酸(5-ASA)结肠定位微丸的体内释药行为,评价其结肠定位释药特性。方法:将5-ASA结肠定位微丸(微丸组)与5-ASA羧甲基纤维素钠混悬溶液(对照组)分别给大鼠灌胃,于规定时间间隔从大鼠心脏取血,并取出胃、小肠、盲肠、结肠及其内容物,计算相对靶向释药指数(DDI值);扫描电镜观察不同部位的微丸表面结构。结果:微丸组在胃、小肠、盲肠、结肠中的DDI值分别为11.09,12.08,187.25,181.68。扫描电镜观察结肠内微丸有清晰可见的孔径。结论:5-ASA结肠定位微丸具有良好的结肠定位释药性。     

响应面分析法优化当归超临界提取物结肠定位微丸的制备工艺研究

采用离子交联法制备当归超临界提取物丸芯,以丸芯载药量和包封率为指标,对影响载药量和包封率的多个因素进行考察,并采用Box-Behnken试验设计和响应面分析法对载药丸芯的处方进行优化,然后进行包衣工艺研究。通过体外释放研究,优选当归超临界提取物结肠定位微丸的包衣工艺及处方并评价其结肠靶向性。确定最佳的丸芯制备工艺∶3%果胶,果胶与卵磷脂比为4∶1,果胶药物比为4∶5,4%的醋酸锌溶液为交联剂,混匀温度35℃,交联温度35℃,交联时间30 min;包衣工艺∶包衣材料为尤特奇FS30D,包衣材料1.5%的柠檬酸三乙酯和聚氧乙烯脱水山梨醇单油酸酯(吐温-80),包衣材料1.2%的单硬脂酸甘油酯,包衣增重15%。最优工艺制备的当归超临界提取物结肠定位微丸在人工胃液中2 h几乎无释放,人工小肠液中4 h释放小于20%,人工结肠液中6 h释放大于90%,说明制备的当归超临界提取物结肠定位微丸具有良好的结肠靶向性。     

������-�Ǿ���˫���������Ƭ���ڽ᳦�������ҩ����о�

目的以壳聚糖为酶触型结肠靶向给药系统的材料,研制可用于结肠靶向的多单元口服给药系统(迷你片),以期为结肠部位疾病治疗的药物输送提供重要参考。方法以结肠癌的治疗药物-吲哚美辛为模型药物,首先制备固体分散体,再采用直接压片法和包衣技术制备尤特奇-壳聚糖双层包衣结肠靶向迷你片,考察靶向迷你片在不同释放介质中的释药行为,采用小动物活体荧光成像技术考察制剂在体内的转运和吸收情况,并以比格犬为动物模型进行药动学研究和生物利用度评价。结果制备的壳聚糖多单元结肠靶向迷你片可以完整形态通过大鼠胃和小肠,并靶向在结肠部位缓慢释放,比格犬体内药动学数据表明,自制结肠靶向迷你片的释药时间显著延长,血药浓度平稳。结论本实验制备尤特奇-壳聚糖双层包衣多单元迷你片给药系统具有较好的结肠靶向性和缓释效果,可为治疗结肠疾病的制剂开发提供重要参考。     

pH依赖-时滞型大黄素结肠定位微丸的制备及体外释药研究

目的制备pH依赖-时滞型大黄素结肠定位微丸并对影响其体外释药的包衣处方因素进行研究。方法采用离心造粒包衣机以粉末层积法制备载药微丸,并通过依次包衣时滞内层(Eudragit RL 30D)和pH依赖外层(Eudragit FS 30D)制备pH依赖-时滞型大黄素结肠定位微丸;以体外释放度为评价指标,采用相似因子(f2)法统计分析释药曲线,考察影响大黄素微丸体外释药的处方因素。结果最佳时滞层包衣液处方为:Eudragit RL 30D增重5%,HPMC用量60%,滑石粉用量50%,柠檬酸三乙酯用量15%;最佳pH依赖层包衣液处方为:Eudragit FS 30D增重4.6%,滑石粉用量50%,柠檬酸三乙酯用量5%。体外释放度实验表明,pH依赖-时滞型大黄素结肠定位微丸在人工胃液中2 h和人工肠液中3 h的累积释药率小于10%,人工结肠液7 h内基本释放完全,具有明显的结肠定位释药特性。结论通过调整时滞层及pH依赖层包衣厚度可以制备pH依赖-时滞型大黄素结肠定位微丸。     

头孢克洛缓释微丸制备、体外释放及人体药动学评价

 目的 制备头孢克洛缓释微丸,并研究其体外释放行为及人体药动学。方法 采用包衣锅滚丸法制备头孢克洛载药微丸, 以不同类型和比例的丙烯酸树脂及Surelease作为缓释包衣材料并以流化床对载药微丸进行包衣,对最终确定处方的成品进行体外释放和20例健康受试者的生物等效性研究,求算体内药动学参数。结果 以Surelease包衣增重15％,其体外释放行为符合一级释放方程,制备的头孢克洛缓释微丸和上市对照相比生物等效。结论 本方法适于制备较大剂量的缓释微丸,工艺可行,头孢克洛缓释微丸和市售对比体内生物等效。     

黄芪多糖-Eudragit S100结肠定位释放喷雾干燥粉的制备和体外溶出评价

目的 拟制备pH依赖型黄芪多糖结肠定位释放喷雾干燥粉,以期达到结肠定位释药的目的。方法 以Eudragit S100水分散体为结肠靶向材料制备黄芪多糖结肠定位释放喷雾干燥粉,考察其体外释药性能,并对其进行扫描电镜（SEM）分析。结果 药物与Eudragit S100比例为1∶10时所制备的喷雾干燥粉在模拟人工胃液中基本不释药,在模拟人工肠液中,药物4 h的累积溶出率小于30.0%,在模拟人工结肠液中,1 h的体外累积溶出率达90.0%以上。结论 以Eudragit S100水分散体为载体制备的黄芪多糖结肠定位释放喷雾干燥粉达到了结肠定位释药的效果,其制备工艺简单、可行。     

Auraptene Induces Apoptosis via Myeloid Cell Leukemia 1‐Mediated Activation of Caspases in PC3 and DU145 Prostate Cancer Cells

Although auraptene, a prenyloxy coumarin from Citrus species, was known to have anti‐oxidant, anti‐bacterial, antiinflammatory, and anti‐tumor activities, the underlying anti‐tumor mechanism of auraptene in prostate cancers is not fully understood to date. Thus, in the present study, we have investigated the anti‐tumor mechanism of auraptene mainly in PC3 and DU145 prostate cancer cells, because auraptene suppressed the viability of androgen‐independent PC3 and DU145 prostate cancer cells better than androgen‐sensitive LNCaP cells. Also, auraptene notably increased sub‐G1 cell population and terminal deoxynucleotidyl transferase dUTP nick end labeling‐positive cells as features of apoptosis in two prostate cancer cells compared with untreated control. Consistently, auraptene cleaved poly(ADP‐ribose) polymerase, activated caspase‐9 and caspase‐3, suppressed the expression of anti‐apoptotic proteins, including Bcl‐2 and myeloid cell leukemia 1 (Mcl‐1), and also activated pro‐apoptotic protein Bax in both prostate cancer cells. However, Mcl‐1 overexpression reversed the apoptotic effect of auraptene to increase sub‐G1 population and induce caspase‐9/3 in both prostate cancer cells. Taken together, the results support scientific evidences that auraptene induces apoptosis in PC3 and DU145 prostate cancer cells via Mcl‐1‐mediated activation of caspases as a potent chemopreventive agent for prostate cancer prevention and treatment. Copyright © 2017 John Wiley & Sons, Ltd.     

基于硫氧还蛋白还原酶1探究堆心菊灵对人前列腺癌细胞中活性氧产生的影响

目的 探究堆心菊灵在人前列腺癌细胞中的抗癌作用及其潜在的作用机制。方法 人前列腺癌DU145和PC-3细胞分别以不同浓度的堆心菊灵处理48 h,CCK-8法检测细胞存活率;qRT-PCR法检测硫氧还蛋白还原酶1(thioredoxin reductase1,TrxR1)m RNA表达情况。从人类蛋白免疫组化表达数据库中检测前列腺癌组织和正常组织中TrxR1蛋白表达情况;经堆心菊灵或活性氧（reactive oxygen species,ROS）抑制剂处理后,采用DCFH-DA染色法检测ROS的产生;敲除或过表达TrxR1,经堆心菊灵处理后,检测2种细胞中ROS水平。结果 堆心菊灵显著抑制前列腺癌细胞存活率和TrxR1 m RNA表达水平（P<0.05、0.001）,呈剂量相关性。与正常组织相比,TrxR1在前列腺癌组织中高表达。堆心菊灵显著诱导了前列腺癌细胞中ROS的产生,敲除TrxR1显著提高了前列腺癌细胞中ROS水平,过表达TrxR1抑制了前列腺癌细胞中ROS产生;而堆心菊灵可改善TrxR1过表达对ROS产生的抑制作用。结论 堆心菊灵可以通过靶向人前列腺癌细胞中的TrxR1来...     

广藿香醇对人雄激素非依赖性前列腺癌细胞DU145生长的抑制作用及机制

目的:观察广藿香醇(pachouli alcohol,PA)对人雄激素非依赖性前列腺癌细胞DU145的凋亡诱导效应及增殖抑制作用,探讨其发生机制。方法:广藿香醇10,20,40,80,160 mg·L-1作用在密度为6×107/L DU145细胞24,48,72 h后,采用四甲基偶氮唑盐法(MTT)检测广藿香醇对细胞的生长抑制作用;透射电镜观察药物诱导细胞凋亡形态变化;Annexin V-FITC,PI双标记法流式细胞仪检测药物诱发细胞凋亡的改变;Western blot检测半胱氨酸天冬氨酸蛋白酶3(Caspase-3)、B细胞淋巴瘤/白血病-2蛋白(Bcl-2)、Bcl-2关联X蛋白(Bax)、凋亡抑制蛋白Livin的表达。结果:MTT法检测提示广藿香醇处理组细胞增殖抑制作用明显,10,20,40,80,160 mg·L-1广藿香醇对DU145的24,48,72 h抑制率分别为5.73%,16.67%,22.61%;13.42%,25.03%,39.68%;25.92%,31.46%,52.76%;39.61%,54.68%,73.52%;56.42%,77.35%,91.58%,呈剂量-时间依赖性(P<0.05)。透射电镜显示药物作用后细胞出现凋亡形态改变。流式细胞仪检测提示广藿香醇作用使细胞凋亡率明显升高,与对照组比较有统计学意义(P<0.05)。Western blot检测提示广藿香醇可增强细胞Caspase-3,Bax的表达,下调Livin,Bcl-2蛋白的表达。结论:广藿香醇能抑制DU145细胞增殖,其作用机制可能与诱导细胞凋亡效应有关。     

中药紫龙金对前列腺癌细胞体外增殖和侵袭的抑制作用

目的探讨复方中药紫龙金对前列腺癌的体外增殖和侵袭的抑制作用。方法通过绘制生长曲线、软琼脂集落生长试验评价紫龙金对人前列腺癌细胞系的增殖抑制、集落生长抑制作用；应用Tran- sWell细胞培养小室评价紫龙金的侵袭抑制作用；应用Western blot方法检测紫龙金对细胞间黏附分子-1 (intercellular adhesion molecule-1,ICAM-1)和上皮型钙黏蛋白(epithelial cadherin,E-Cadherin)表达的影响。结果紫龙金对3种前列腺癌细胞系均具有剂量依赖性增殖抑制作用,紫龙金0．5 mg/ml作用6天对LN- CaP、DU-145和PC-3的抑制率分别为78．0%、87．9%和81．0%；紫龙金0．1 mg/ml可以显著抑制DU-145细胞的软琼脂集落生长,抑制率为87．9%；紫龙金0．5 mg/ml作用12h对DU-145细胞体外侵袭抑制率为44．5%；紫龙金可以剂量依赖性上调LNCaP和DU-145细胞ICAM-1和E-Cadherin表达。结论紫龙金具有抑制前列腺癌细胞增殖、降低集落生长和体外侵袭能力,其作用可能是通过增加ICAM-1和E-Cadherin...     

Brazilian red propolis exerts a cytotoxic action against prostate cancer cells and upregulates human monocyte functions

Different propolis samples can be obtained in Brazil, such as green, brown and red. Studies related to Brazilian red propolis (BRP) have increased in the last few years, so the aim of this study was to investigate its effects on the prostate cell lines LNCaP and PC-3 and on human monocytes. BRP chemical composition was analyzed by HPLC-DAD, the viability of monocyte and cancer cell by MTT assay. Cytokine production (TNF-α, IL-1β, IL-6, IL-10) by monocytes was quantitated by ELISA, the expression of cell markers (TLR-2, TLR-4, HLA-DR, CD80) and reactive oxygen species by flow cytometry. The candidacidal activity and the effects of supernatant of treated monocytes on tumor cells were assessed. BRP affected LNCaP viability after 48 and 72 h, while PC-3 cells were more resistant over time. BRP upregulated CD80 and HLA-DR expression, and stimulated TNF-α, IL-6 and IL-10 production. BRP enhanced the fungicidal activity of monocytes, displayed an antioxidant action and the supernatant of BRP-treated monocytes diminished LNCaP viability. In the search for new immunomodulatory and antitumoral agents, BRP exerted a selective cytotoxic activity on prostate cancer cells and an immunomodulatory action, suggesting its potential for clinical trials with oncological patients and for the discovery of new immunomodulatory and antitumor drugs.     

Artocarpus altilis (Parkinson) Fosberg Extracts and Geranyl Dihydrochalcone Inhibit STAT3 Activity in Prostate Cancer DU145 Cells

Artocarpus altilis (Parkinson) Fosberg has traditionally been used in Indonesia for the treatment of liver cirrhosis, hypertension, and diabetes. In many other countries, it is used for the treatment of malaria, yellow fever, and dengue fever. It has been reported that A. altilis extracts have antiatherosclerotic and cytoprotective effects, but its molecular targets in tumor cells are not yet fully understood. The A. altilis extracts and the partially purified fraction have been shown to inhibit STAT3 activity and the phosphorylation of STAT3 in a dose‐dependent manner. To identify the active components, a bioassay‐guided isolation of the partially purified fraction resulted in the identification of a geranyl dihydrochalcone, CG901. Its chemical structure was established on the basis of spectroscopic evidence and comparison with published data. The partially purified fraction and the isolated a geranyl dihydrochalcone, CG901, down‐regulated the expression of STAT3 target genes, induced apoptosis in DU145 prostate cancer cells via caspase‐3 and PARP degradation, and inhibited tumor growth in human prostate tumor (DU145) xenograft initiation model. These results suggest that A. altilis could be a good natural source and that the isolated compound will be a potential lead molecule for developing novel therapeutics against STAT3‐related diseases, including cancer and inflammation. Copyright © 2015 John Wiley & Sons, Ltd.     

In vitro anti-prostate cancer and ex vivo antiangiogenic activity of Vernonia guineensis Benth. (Asteraceae) tuber extracts

Ethnopharmacological relevance

Prostate cancer is a major problem worldwide and affects most men above the age of forty-five. Vernonia guineensis Benth. (Asteraceae) root decoction is used in folk medicine in Cameroon to treat a number of ailments including prostate cancer. The aim of this study was to provide a preliminary validation of the use of Vernonia guineensis Benth. extracts to treat prostate cancer by evaluating the in vitro activity of its crude extracts and isolated molecules on prostate cancer cells lines and effect on angiogenesis which is essential for growth and metastases of prostate cancer.

Materials and methods

Aqueous, dichloromethane and methanol extracts of Vernonia guineensis Benth. tubers were tested for activity against three prostate cancer cell lines (PC-3, DU-145 and AT3B-1). The dichloromethane extract was subjected to bioactivity guided fractionation. Anti-proliferation, clonogenic and antiangiogenic activity of the crude extracts and isolated compound were tested. The WST-1 assay was used for the anti-proliferation activity meanwhile the standard clonogenic test and the rat ring aorta assay were carried out to determine the clonogenic and antiangiogenic activity of tested products respectively.

Results

The aqueous and methanol extracts of Vernonia guineensis Benth. demonstrated weak activity against prostate cancer cell lines in vitro with IC₅₀ > 100 μg/mL. The dichloromethane extract was more potent with IC₅₀ of 56.233 ± 3.630 μg/ml and 67.316 ± 2.452 μg/ml against the DU-145 and PC-3 cell lines respectively. Activity guided fractionation of this extract yielded a Pentaisovalerylsucrose (1) isolated for the first time from a natural source to the best of our knowledge. Compound 1 demonstrated in vitro activity against the human prostate cancer cell lines PC-3 and DU-145 with IC₅₀ of 5.701 ± 0.142 μM and 4.275 ± 0.710 μM, respectively. The IC₅₀ of the compound was 5.763 ± 0.425 μM against AT3B-1, a rat prostate cancer cell line expressing P-glycoprotein which is linked to drug resistance in most metastatic cancers. Compared to compound 1, Paclitaxel and Docetaxel were active against AT3B-1 at 2.641 ± 1.253 μM and 0.613 ± 0.251 μM. Paclitaxel showed IC₅₀ values of 0.004 ± 0.002 μM and 0.003 ± 0.001 μM against DU-145 and PC-3 prostate cancer cell lines respectively. Docetaxel showed IC₅₀ values of 0.002 ± 0.001 μM and 0.004 ± 0.001 μM against DU-145 and PC-3 prostate cancer cell lines respectively.

Conclusion

The in vitro anti-prostate cancer and the antiangiogenic activity of Vernonia guineensis Benth. extracts and isolated compound support the use of the tubers of this plant for the treatment of prostate cancer.     

没药中环阿尔廷烷型三萜的生物转化研究

目的:对爱伦堡没药中分离获得的环阿尔廷-24-烯-1α,2α,3β-三醇开展生物转化研究,以期获得抗肿瘤活性好、结构新颖的环阿尔廷烷型三萜衍生物。方法:采用马铃薯培养基,将底物加入到14株菌株培养液中,27.8℃培养7 d,以TLC检测产物,筛选具有转化能力的菌株;选择微紫青霉开展制备级转化试验,27.8℃培养10d,乙酸乙酯萃取后,硅胶柱色谱分离纯化转化产物,以质谱、核磁共振波谱确定其结构,并采用MTT法测定其对人前列腺癌细胞株生长抑制作用。结果:微紫青霉对底物进行了转化,获得了两个新的环阿尔廷烷型三萜,产率为21.15%;产物对人前列腺癌细胞PC3和DU145具有生长抑制作用,IC50值为14.5和27.8μmol/L。结论:环阿尔廷烷型三萜能被微紫青霉生物转化,产生两个新的羟基化衍生物。     

补肾抑瘤汤含药血清对PC-3细胞Notch1/Jagged1信号通路的影响

目的:通过体外细胞实验研究补肾抑瘤汤对前列腺癌细胞增殖的干预作用及其机制。方法:首先按照血清药理学方法,给予SD大鼠连续灌胃用药7 d,取血制备空白血清和补肾抑瘤汤含药血清;然后以人前列腺癌细胞PC-3为模型研究补肾抑瘤汤含药血清对前列腺癌细胞增殖及Notch1/Jagged1信号通路的影响,噻唑蓝(MTT)比色法检测补肾抑瘤汤含药血清(2.5%,5%,10%,15%)处理PC-3细胞后不同时间点(12,24,36 h)的细胞增殖情况,分别应用逆转录-聚合酶链式反应(RTPCR)及蛋白免疫印迹法(Western blot)分析补肾抑瘤汤含药血清对PC-3细胞Notch1,Jagged1 mRNA和蛋白表达的影响。结果:与空白组比较,经补肾抑瘤汤含药血清处理12,24,36 h后,PC-3细胞增殖受到了不同程度的抑制,其中以36 h的抑制作用最为显著(P0.01);补肾抑瘤汤含药血清对PC-3细胞Notch1,Jagged1 mRNA和蛋白表达均有抑制作用,尤其是补肾抑瘤汤10%,15%含药血清组抑制效果明显(P0.05,P0.01)。结论:补肾抑瘤汤含药血清能明显抑制PC-3细胞增殖,作用可能与调控Notch1/Jagged1表达有一定相关性。     

昆布多糖硫酸酯对非激素依赖型人前列腺癌细胞PC-3的作用研究

目的研究昆布多糖硫酸酯(LAMS)对体外培养的非激素依赖型人前列腺癌细胞株PC-3的作用。方法利用WST-8法检测LAMS对体外培养的非激素依赖型人前列腺癌细胞株PC-3细胞生长的抑制作用,利用流式细胞术(FCM)分析LAMS对细胞周期和凋亡的影响,利用荧光显微镜观察PC-3细胞形态。结果随着LAMS浓度的增加和作用时间的延长,对非激素依赖型人前列腺癌细胞株PC-3细胞的生长抑制率逐渐增高,呈时间-剂量效应;流式细胞仪分析,PC-3细胞凋亡率逐渐增高;但PC-3细胞的凋亡率与作用时间的延长无明显关系;荧光显微镜观察,PC-3细胞凋亡小体逐渐增多,甚至出现细胞死亡;随着LAMS浓度增加PC-3细胞G1期细胞比例逐渐减少,S+G2期细胞比例呈剂量依赖性增加,表明存在S+G2期阻滞。结论LAMS能抑制体外PC-3细胞的生长,并促进其S+G2期阻滞和凋亡,可能是其抑制前列腺癌的机制之一。